| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2006
|
16.25
|
|
2
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
|
3
|
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
|
J Natl Cancer Inst
|
2005
|
7.70
|
|
4
|
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
|
J Clin Oncol
|
2007
|
6.11
|
|
5
|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
5.81
|
|
6
|
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
|
Lancet Oncol
|
2007
|
5.39
|
|
7
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
8
|
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
|
Lancet Oncol
|
2010
|
4.81
|
|
9
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
10
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
|
J Clin Oncol
|
2009
|
3.99
|
|
11
|
Projecting individualized absolute invasive breast cancer risk in African American women.
|
J Natl Cancer Inst
|
2007
|
3.93
|
|
12
|
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
J Clin Oncol
|
2010
|
3.79
|
|
13
|
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
|
J Natl Cancer Inst
|
2011
|
3.54
|
|
14
|
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
|
Lancet
|
2013
|
3.31
|
|
15
|
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
|
J Clin Oncol
|
2009
|
2.95
|
|
16
|
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.
|
Lancet Oncol
|
2012
|
2.65
|
|
17
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
18
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
|
19
|
Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
|
J Surg Oncol
|
2010
|
2.52
|
|
20
|
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
|
J Urol
|
2009
|
2.41
|
|
21
|
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
2.38
|
|
22
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
|
J Clin Oncol
|
2012
|
2.34
|
|
23
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
24
|
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
|
J Clin Oncol
|
2011
|
2.26
|
|
25
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
26
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
|
27
|
Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
|
J Clin Oncol
|
2011
|
2.00
|
|
28
|
Nonparametric inference on median residual life function.
|
Biometrics
|
2007
|
1.90
|
|
29
|
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
|
Am J Obstet Gynecol
|
2005
|
1.83
|
|
30
|
Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.
|
J Clin Oncol
|
2007
|
1.77
|
|
31
|
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
|
Cancer Prev Res (Phila)
|
2012
|
1.63
|
|
32
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
|
33
|
Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
|
Breast Cancer Res Treat
|
2008
|
1.56
|
|
34
|
Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.
|
J Clin Oncol
|
2010
|
1.54
|
|
35
|
Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.
|
J Natl Cancer Inst
|
2011
|
1.51
|
|
36
|
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
|
Am J Obstet Gynecol
|
2011
|
1.48
|
|
37
|
Is sentinel node biopsy necessary in conservatively treated DCIS?
|
Ann Surg Oncol
|
2007
|
1.48
|
|
38
|
Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models.
|
Pharm Stat
|
2012
|
1.43
|
|
39
|
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2011
|
1.32
|
|
40
|
Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk.
|
Am J Physiol Heart Circ Physiol
|
2004
|
1.30
|
|
41
|
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
|
Ann Surg Oncol
|
2010
|
1.27
|
|
42
|
Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women.
|
Breast Cancer Res Treat
|
2007
|
1.27
|
|
43
|
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
|
J Natl Cancer Inst
|
2006
|
1.27
|
|
44
|
Lower-category benign breast disease and the risk of invasive breast cancer.
|
J Natl Cancer Inst
|
2004
|
1.19
|
|
45
|
Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.
|
Cancer Prev Res (Phila)
|
2011
|
1.19
|
|
46
|
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
|
Clin Cancer Res
|
2008
|
1.13
|
|
47
|
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
|
Cancer Discov
|
2013
|
1.12
|
|
48
|
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
|
Genet Epidemiol
|
2011
|
1.06
|
|
49
|
Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.
|
Am J Clin Pathol
|
2007
|
1.06
|
|
50
|
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.
|
Clin Breast Cancer
|
2008
|
1.04
|
|
51
|
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
|
J Natl Cancer Inst
|
2006
|
1.03
|
|
52
|
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.
|
Br J Haematol
|
2003
|
1.00
|
|
53
|
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
|
Clin Cancer Res
|
2011
|
0.98
|
|
54
|
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.
|
J Natl Cancer Inst
|
2003
|
0.98
|
|
55
|
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
|
J Clin Oncol
|
2010
|
0.96
|
|
56
|
Breast cancer risk factors and mammographic breast density in women over age 70.
|
Breast Cancer Res Treat
|
2005
|
0.96
|
|
57
|
25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1.
|
Breast Cancer Res Treat
|
2012
|
0.94
|
|
58
|
Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches.
|
J Clin Oncol
|
2007
|
0.91
|
|
59
|
The use of tamoxifen and raloxifene for the prevention of breast cancer.
|
Recent Results Cancer Res
|
2009
|
0.89
|
|
60
|
Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
|
J Clin Oncol
|
2006
|
0.89
|
|
61
|
Multivariate predictors of failed prehospital endotracheal intubation.
|
Acad Emerg Med
|
2003
|
0.89
|
|
62
|
Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.
|
Int J Mol Epidemiol Genet
|
2010
|
0.88
|
|
63
|
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
|
Clin Cancer Res
|
2003
|
0.87
|
|
64
|
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
|
Clin Breast Cancer
|
2002
|
0.86
|
|
65
|
Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21.
|
Cancer
|
2007
|
0.86
|
|
66
|
Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study.
|
Cancer Prev Res (Phila)
|
2013
|
0.84
|
|
67
|
Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial.
|
J Am Stat Assoc
|
2007
|
0.84
|
|
68
|
Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.
|
Cancer Epidemiol Biomarkers Prev
|
2014
|
0.84
|
|
69
|
The impact of systemic therapy following ductal carcinoma in situ.
|
J Natl Cancer Inst Monogr
|
2010
|
0.83
|
|
70
|
Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer.
|
J Natl Cancer Inst
|
2008
|
0.83
|
|
71
|
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
|
Breast Cancer Res Treat
|
2013
|
0.83
|
|
72
|
Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
|
J Natl Cancer Inst
|
2002
|
0.82
|
|
73
|
Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data.
|
Cancer Invest
|
2006
|
0.80
|
|
74
|
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
|
Cancer Prev Res (Phila)
|
2012
|
0.79
|
|
75
|
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
|
J Natl Cancer Inst Monogr
|
2010
|
0.79
|
|
76
|
Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation" Int J Radiat Oncol Biol Phys 2009;75:1290-1296).
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.77
|
|
77
|
Is tamoxifen a risk factor for retinal vaso-occlusive disease?
|
Retina
|
2005
|
0.76
|
|
78
|
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
|
Semin Oncol
|
2008
|
0.75
|
|
79
|
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
80
|
The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project.
|
World J Surg
|
2006
|
0.75
|